Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.63 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 8/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230694 | 1.00 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL4126013 | 1.00 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL6043443 | 0.89 | PPARA (0.57) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL27422193 | 0.89 | PPARA (0.65) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL6043704 | 0.87 | PPARA (0.55) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL6043402 | 0.87 | PPARA (0.55) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL22980587 | 0.86 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL22980586 | 0.86 | PPARA (0.63) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL28763859 | 0.84 | PPARA (0.60) | PPARACTSSPPARGCTSKATM | |
| SCHEMBL22990674 | 0.84 | PPARA (0.60) | PPARACTSSPPARGCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895497-B2 | Cathepsin S inhibitors | DCB-USA, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895497-B2 | Cathepsin S inhibitors | DCB-USA, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895497-B2 | Cathepsin S inhibitors | DCB-USA, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8741938-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBVIE INC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524753-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBOTT LABORATORIES (US) | 2012-07-19 | — | — | US | disclosed |
| US-8133892-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | DCB-USA, LLC (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | DCB-USA, LLC (US) | 2011-07-07 | — | — | US | disclosed |
| US-7786153-B2 | Compounds that are useful for improving pharmacokinetics | ABBOTT LABORATORIES INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-7713961-B2 | Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7709484-B1 | Substituted melanocortin receptor-specific piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| WO-2009038411-A2 | BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY | LG LIFE SCIENCES, LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| EP-1866034-A1 | SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| US-20060223759-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103038-A1 | SUBSTITUTED 1,2-ETHYLENDIAMINES, MEDICAMENTS COMPRISING SAID COMPOUND; THEIR USE AND THEIR METHOD OF MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184559-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | PPARA 4156/4885CTSS 2351/4885PPARG 3359/4885 |
| US-20060223759-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | PPARA 3435/4885CTSS 1930/4885PPARG 3691/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | PPARA 4156/4885CTSS 2351/4885PPARG 3359/4885 |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | PPARA 4156/4885CTSS 2351/4885PPARG 3359/4885 |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | PSEN1, PSEN2, BACE1 | PPARA 3435/4885CTSS 1930/4885PPARG 3691/4885 |
| US-20090325940-A1 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof | PSEN1, PSEN2, BACE1 | PPARA 3435/4885CTSS 1930/4885PPARG 3691/4885 |
| US-20110166141-A1 | CATHEPSIN S INHIBITORS | CTSS, CTSV, CTSB | PPARA 3183/4885CTSS 1/4885PPARG 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.